Notice of Completion of Stock Acquisitions of Nihon Eyedrops Research Institute Co., Ltd.

ROHTO Pharmaceutical Co., Ltd. ("ROHTO Pharmaceutical"), with the aim of expanding its presence in the ophthalmology field, completed the acquisition of all shares of Nihon Eyedrops Research Institute Co., Ltd. ("Nihon Eyedrops Research Institute") on March 2nd. Nihon Eyedrops Research Institute has now become a subsidiary of ROHTO Pharmaceutical, and we are pleased to inform you of this development.

Nihon Eyedrops Research Institute, established in 1961, is primarily engaged in the manufacturing and sale of medical ophthalmic eyedrops. Since its inception, the company has been dedicated to the research and development of "eye-friendly eyedrops," leading the way with innovations such as the "PF Delami Container" for preservative-free eyedrops and a strong production infrastructure backed by advanced manufacturing technology. They also maintain a nationwide distribution network to supply ophthalmologists across the country.

Through this stock acquisition, the combined strengths of Nihon Eyedrops Research Institute's technology and ROHTO Pharmaceutical's position as a leader in over-the-counter eyedrops will be synergistically leveraged. This will serve as the foundation for our ophthalmology business in the medical field, contributing to the eye care of people everywhere.